Immunoassay News and Research

RSS

NIH provides scale-up and manufacturing support for new COVID-19 testing technologies

The National Institutes of Health today announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of its Rapid Acceleration of Diagnostics (RADx) initiative.

2 Sep 2020

Brazilian state of Maranhão heading towards SARS-CoV-2 herd immunity, say researchers

Researchers at the Federal University of Maranhão, Brazil, have conducted a study suggesting that the state of Maranhão is well on its way to acquiring herd immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020

Promega introduces new serological antibody test for COVID-19

Promega Corporation today announced the launch of its new serological antibody test for COVID-19 to detect the presence of antibodies against the SARS-CoV-2 virus.

From Promega Corporation 13 Aug 2020

Fujirebio announces launch of clinical testing for new SARS-CoV-2 Antigen assay

Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc, announced today the initiation of clinical testing needed for the submission of its new SARS-CoV-2 Antigen assay for EUA (Emergency Use Authorization) from the U.S. Food and Drug Administration.

6 Aug 2020

NIH invests $248.7 million in new COVID-19 testing technologies to meet U.S. demand

The National Institutes of Health is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus).

31 Jul 2020

COVID-19 test kits offered by Carolina Liquid Chemistries granted FDA emergency use authorization

Carolina Liquid Chemistries, Corp., an innovative leader in clinical diagnostics and drug screening, is now offering test kits for COVID-19 that have been granted Emergency Use Authorization by the US Food and Drug Administration, pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act.

From Carolina Liquid Chemistries Corp. 29 Jul 2020

Inconsistent SARS-CoV-2 antibody results in nephrology workers

Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV-2 seroprevalence among asymptomatic individuals, while this was not the case among Covid-19 patients.

29 Jul 2020

UArizona aims to develop a device for quick and accurate detection of pathogens, biological threats

To better protect individuals serving on the front lines of battlefields or dealing with an event like the current COVID-19 health crisis or potential future pandemics, scientists at the University of Arizona College of Medicine - Phoenix are leading an effort to develop a device for easy, quick and accurate detection of pathogens and biological threats.

28 Jul 2020

SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin. Blood levels of bio-ADM® reflect in real-time the functional status of the endothelium, the inner cell sheet of blood vessels.

24 Jul 2020

SphingoTec introduces a CE-IVD-marked point-of-care test to determine blood levels of bio-ADM

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

22 Jul 2020

New assay improves detection of SARS-CoV-2 antibodies

Researchers at the University of California Santa Cruz have developed a new assay for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that they say provides significant advantages over the techniques currently used.

20 Jul 2020

Study finds significant variability in the accuracy of currently available COVID-19 antibody tests

A new peer-reviewed study by researchers at NSF International and Novateur Ventures finds significant variability in the accuracy of currently available COVID-19 antibody tests.

15 Jul 2020

New technology allows quick and cost-effective identification of cancer biomarkers

A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers.

15 Jul 2020

Novel antibody test for SARS-CoV-2

A team of researchers in the United States have developed highly specific and sensitive assays that could improve understanding of the antibody response in coronavirus disease 2019 (COVID-19) and help to determine the effectiveness of vaccines.

9 Jul 2020

LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector

Today, LGC announced the acquisition of The Native Antigen Company (NAC), one of the world’s leading suppliers of high quality infectious disease antigens and antibodies.

9 Jul 2020

Novel biomarkers required to triage and monitor severely ill COVID-19 patients

Diagnostics company SphingoTec GmbH ("sphingotec") announced today the results of a working group meeting of clinical experts that discussed the utility of sphingotec's diagnostic solutions for acute and critical care in supporting the triage, diagnosis, and management of severely ill COVID-19 patients.

18 Jun 2020

Early neutralizing response to SARS-CoV-2 dominated by IgA antibodies

Researchers from France and the U.S. demonstrated how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection could induce an early and vigorous virus-specific IgA response that paves the way for the production of SARS-CoV-2 IgG antibodies, with even better neutralizing properties. Their paper is currently available on the medRxiv preprint server.

14 Jun 2020

Siemens receives FDA approval for SARS-CoV-2 antibody test

Siemens Healthineers has announced that the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization for its total antibody test to detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, including Immunoglobulin M (IgM) and Immunoglobulin G (IgG) in the blood.

3 Jun 2020

Research provides new evidence for potential blood-based biomarker for Alzheimer's

A potential blood-based biomarker for Alzheimer's and other neurodegenerative diseases seems even more promising thanks to new research from a Massachusetts General Hospital-led study.

27 May 2020

Portable analyzer rapidly detects anti-virus antibody in blood serum

Researchers have succeeded in detecting anti-avian influenza virus antibody in blood serum within 20 minutes, using a portable analyzer they have developed to conduct rapid on-site bio tests. If a suitable reagent is developed, this technology could be used to detect antibodies against SARS-CoV-2, the causative virus of COVID-19.

22 May 2020